A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Public ClinicalTrials.gov record NCT04875975. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Study identification
- NCT ID
- NCT04875975
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Enrollment
- 12 participants
Conditions and interventions
Interventions
- Placebo Drug
- Rozanolixizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 89 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 26, 2021
- Primary completion
- Mar 7, 2024
- Completion
- Apr 25, 2024
- Last update posted
- May 30, 2025
2021 – 2024
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Aie001 50101 | Aurora | Colorado | 80045-2541 | — |
| Aie001 50342 | Jacksonville | Florida | 32224 | — |
| Aie001 50243 | Boston | Massachusetts | 02114-3117 | — |
| Aie001 50047 | Boston | Massachusetts | 02115 | — |
| Aie001 50104 | Rochester | Minnesota | 55905 | — |
| Aie001 50298 | New York | New York | 10016 | — |
| Aie001 50090 | Winston-Salem | North Carolina | 27157 | — |
| Aie001 50311 | Cleveland | Ohio | 44195 | — |
| Aie001 50304 | Dallas | Texas | 75390-8869 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04875975, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 30, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04875975 live on ClinicalTrials.gov.